Course Detail

This series provides vital information for evolving industry to align their services and products with the quality-focused healthcare marketplace.

The Affordable Care Act helped to mark a transition in the United States healthcare system from a focus on volume to a focus on value. This value is being captured through the use of quality measures which have emerged from a variety of healthcare stakeholder groups. Healthcare quality measures are rapidly changing the behaviors of providers, payers, and consumers. This online continuing education series provides a comprehensive overview of the healthcare quality landscape including national priorities, and the complexity of quality measure development, endorsement and implementation. A glossary, visually intuitive diagrams, and testimonials from experts in the field introduce the learner to various programs and initiatives aimed at optimizing resource utilization, eliminate waste, and improving accountability through healthcare quality measurement.

The Healthcare Quality: Measurement and Implications series includes two interactive, online modules representing a comprehensive introduction to the terminology, the trends, the stakeholders and leadership, and the quality improvement programs at play in the current healthcare environment. These two modules represent 3.5 hours of certified continuing education. The modules are available anytime and anywhere through the online portal at www.pharmacists4knowledge.org.

• Healthcare Quality in the United States
• Quality Measurement for the Pharmaceutical Industry

Learning Objectives:
Healthcare Quality in the United States
Participants in the program can expect to achieve the following learning objectives:

1. Define healthcare system quality;
2. Identify four (4) key stakeholders in healthcare quality and align the stakeholder with their roles in the continuous quality improvement cycle;
3. Provide accurate examples of three (3) types of quality measures;
4. Sequence the steps in quality measure development and describe quality measure evaluation criteria that leads to measure endorsement; and
5. Identify and categorize the various CMS healthcare quality improvement programs and explain how such public programs are drivers of quality in the private sector.

Quality Measurement for the Pharmaceutical Industry
Participants in the program can expect to achieve the following learning objectives:

1. Analyze potential implications, advantages and challenges for the pharmaceutical industry of two quality measure case examples, especially those associated with value-based payment programs;
2. Assess a measurement gap and outline proactive, appropriate steps that can be taken by the pharmaceutical industry to support healthcare quality measurement programs, especially in areas where gaps have been noted;
3. Provide two or more examples of how the implementation of new measures or changes to existing measures could have implications for a therapeutic area and possible approaches to respond to those implications;
4. Develop an engagement strategy as a solution to a challenge in quality improvement; and
5. Interpret the impact of potential changes in the landscape for healthcare quality measurement programs and anticipate strategy updates that may be needed.

Registration Fees

	Registration Fee
NPC Members	$249
Government, Academia, Non-Profit	$249
Corporate	$498

Instructors:

• Eleanor Perfetto, PhD, MS, Program Director, Professor of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy
• Matthew Pickering, PharmD, Postdoctoral Fellow, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy

Contributors and Advisers:

• Alicia DeStefano, MS, RN, CPHQ, Merck
• Carol Alter, MD, AstraZeneca
• Christopher Dezii, RN, MBA, CPHQ, Bristol-Myers Squibb
• Nancy Witkowski, RN, BSN, CCM, CCP, Boehringer Ingelheim
• Terry Livingston, PharmD, Biogen Idec
• Patricia Marchlowska, RN, BSM, Lilly
• Kathy Gans-Brangs, PhD, AstraZeneca

Program Contributors and Advisers/Conflict of Interest Disclosure
It is the policy of the University of Maryland School of Pharmacy Office of Continuing Pharmacy Education to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, all persons in a position to control activity content of continuing pharmacy education activities must disclose their financial relationships with commercial interests relevant to the content of the CPE activity. No Conflicts of interest were identified by the Office of Continuing Pharmacy Education. Disclosures of the faculty and planning committee members are noted for all learners in the designated section of each educational module.

ACCME Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society, and University of Maryland School of Pharmacy. MedChi is accredited by the ACCME to provide continuing medical education for physicians.

MedChi designates this live educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE: 3.5 Contact Hours
UAN: 0025-0000-16-008-H04-P
Expiration Date: 2/16/2019
Program Number: KE-CN-NPC-S01

Questions? Call or Email us at 410-706-3381 or [email protected]

Click here for additional course details.